Drug Profile
Ofatumumab - Genmab/Novartis
Alternative Names: Anti-CD20 monoclonal antibody - Genmab; Arzerra; GSK-1841157; HuMax CD20; Kesimpta; OMB-157Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genmab
- Developer Genmab; GlaxoSmithKline; Mundipharma International; National Cancer Centre (Singapore); Novartis; Roswell Park Cancer Institute; University Health Network
- Class Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
- Phase III B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Phase II Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Suspended Neuromyelitis optica
- Discontinued Pemphigus vulgaris; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
Most Recent Events
- 11 Oct 2023 6 months interim efficacy, adverse events and pharmacodynamics data from the phase III OLIKOS open-label extension trial in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2023)
- 11 Oct 2023 Pooled efficacy data from a phase III ASCLEPIOS I/II trial in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2023)
- 11 Oct 2023 Updated pooled adverse events and pharmacodynamics data from the core trials and phase III ALITHIOS open-label extension trial in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2023)